Legend Biotech
LEGN
77 hedge funds and large institutions have $1.04B invested in Legend Biotech in 2020 Q2 according to their latest regulatory filings, with 77 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
9.32% more ownership
Funds ownership: 0% → 9.32% (+9.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
+$139M |
| 2 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$119M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$97M |
| 4 |
CII
Capital International Inc
Los Angeles,
California
|
+$78.9M |
| 5 |
JJIJ
Johnson & Johnson Innovation - JJDC
New Brunswick,
New Jersey
|
+$63.6M |
Top Sellers
LEGN Hedge Fund Activity: Q2 2020 in Review
77 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Legend Biotech (LEGN) for Q2 2020, worth a combined $1.04B.
Buyers outnumbered sellers: 77 funds opened new LEGN positions and 0 closed out — a net gain of 77 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Vivo Capital, opening a new position worth an estimated $139M.
- 77 institutional investors held Legend Biotech (LEGN) as of Q2 2020, up from 0 in Q1 2020.
- Funds reported $1.04B of Legend Biotech stock for Q2 2020.
- 77 funds opened new Legend Biotech positions in Q2 2020 and 0 closed out, a net change of +77 holders.
- The largest Legend Biotech buyer in Q2 2020 was Vivo Capital, an estimated $139M added.
Based on aggregated 13F filings for Q2 2020.